IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript Summary
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript Summary
GAAP diluted earnings per share for Q3 2024 remained stable at $0.40, with non-GAAP diluted earnings per share at $0.43.The following is a summary of the IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript:
以下是iradimed公司（IRMD）2024年第三季度業績會記錄摘要：
Financial Performance:
金融業績：
IRadimed reported Q3 2024 revenue of $18.3 million, an increase of 11% over Q3 2023.
Gross profit margin for Q3 2024 was impressive at 77.4%.
GAAP diluted earnings per share for Q3 2024 remained stable at $0.40, with non-GAAP diluted earnings per share at $0.43.
Projected fourth quarter 2024 revenue ranging from $18.8 million to $19.2 million, with revised GAAP earnings per share guidance of $1.49 to $1.52 and non-GAAP earnings per share of $1.64 to $1.67.
IRadimed報告2024年第三季度營業收入1830萬美元，較2023年第三季度增長11%。
2024年第三季度毛利潤率達到驚人的77.4%。
2024年第三季度GAAP攤薄每股收益保持穩定，爲0.40美元，非GAAP攤薄每股收益爲0.43美元。
預計2024年第四季度營業收入範圍爲1880萬至1920萬美元，修訂後的GAAP每股收益指導爲1.49至1.52美元，非GAAP每股收益爲1.64至1.67美元。
Business Progress:
業務進展：
Continued strength in IV pump sales driving revenue.
The company has filed for FDA clearance for the new pump, with an anticipated approval in Q2 2025 and expecting initial revenue from the new product in Q4 2025.
Building of new headquarters on schedule, enhancing production capabilities for new pump launch.
持續強勁的靜脈泵銷售推動營業收入。
公司已經申請新泵的FDA許可，預計將在2025年第二季度獲得批准，並預計將在2025年第四季度從新產品獲得初步營業收入。
新總部的建設按計劃進行，增強新泵推出的生產能力。
Opportunities:
機會：
Domestic sales growth at 9% and international sales increasing by 22%, indicating successful market expansion strategies.
Preparing to increase focus on monitor sales to balance product line offerings.
國內銷售增長9%，國際銷售增長22%，表明成功的市場拓展策略。
準備增加對監護器銷售的關注，以平衡產品線的供應。
Risks:
風險：
Potential downturn in sales for the existing pump model as transition to new pump model approaches, with plans to manage revenue dips through enhanced sales of monitors.
隨着向新泵型號過渡的計劃逐漸接近，現有泵型號銷售潛在下降，通過增加監護器銷售來應對營業收入下滑的計劃。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
